Gilead (GILD) says bictegravir & lenacapavir single-tablet regimen maintained virological suppression in people with HIV

Gilead's announcement regarding the effectiveness of its bictegravir and lenacapavir regimen is a positive development for their HIV treatment portfolio.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

US government to meet with robot-makers as China competition intensifies, according to Semafor

CME says Globex Natural Gas futures and options markets will pre-open at 12:45 CT and open at 12:50 CT (13:45 and 13:50EST, 18:45 and 18:50 GMT)

Gilead (GILD) says bictegravir & lenacapavir single-tablet regimen maintained virological suppression in people with HIV

Supermicro (SMCI) and VAST Data Launch a New Enterprise AI Data Platform Solution with NVIDIA to Accelerate AI Factory Deployment

Fed's Musalem (2028 voter, hawk) says inflation is almost a full percentage point above target and the labour market cooling in an orderly way

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • BIC/LEN was generally well tolerated, with no significant or new safety concerns identified
Context

The successful maintenance of virological suppression and the absence of new safety concerns could bode well for future sales and reinforce investor confidence in their product pipeline. It may also indicate potential competitive advantages in the biotechnology sector, particularly among peers focusing on HIV treatments.

Related headlines

The whole workspace, free to try.

Try it free